Antares Pharma Inc. (ATRS)
NASDAQ: ATRS
· Real-Time Price · USD
5.59
0.01 (0.18%)
At close: Apr 24, 2025, 3:47 PM
Antares Pharma Revenue Breakdown
| Period Ending | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|
| Licensing And Development Revenue Revenue | 19.62M | 14.47M | 7.53M | 6.75M |
| Licensing And Development Revenue Revenue Growth | +35.65% | +92.14% | +11.49% | n/a |
| Product Revenue | 126.67M | 113.83M | 92.1M | 47.87M |
| Product Revenue Growth | +11.27% | +23.59% | +92.40% | n/a |
| Royalty Revenue | 37.69M | 21.3M | 24.23M | 8.93M |
| Royalty Revenue Growth | +76.97% | -12.10% | +171.32% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 5.69M | 3.81M | 3.46M | 6.16M | 5.06M | 6.12M | 6.03M | 21.41M | 3.9M | 4.94M |
| Europe Revenue Growth | +49.40% | +10.02% | -43.76% | +21.66% | -17.26% | +1.51% | -71.85% | +448.76% | -20.98% | n/a |
| Other Geographical Area Revenue | n/a | 145.79M | 170K | 364K | 530K | 573.71K | 403.59K | 4.76M | 237.22K | n/a |
| Other Geographical Area Revenue Growth | -100.00% | +85658.24% | -53.30% | -31.32% | -7.62% | +42.15% | -91.52% | +1907.26% | n/a | n/a |
| United States Revenue | 178.29M | n/a | 120.23M | 57.03M | 48.92M | 45.53M | n/a | 330.61K | n/a | n/a |
| United States Revenue Growth | n/a | n/a | +110.81% | +16.57% | +7.45% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 20.6M | 18.67M | 19.87M | 17.7M | 17.61M | 16.66M | 15.23M | 14.45M | 16.42M | 15.37M | 16.39M | 15.09M | 14.94M | 13.16M | 8.33M | 7.46M | 7.82M | 7.34M | 8.19M | 7.36M | 7.47M | 6.15M | 5.62M | 7.01M | 7.6M | 6.68M | 6.61M | 6.61M | 7.04M |
| Selling, General, and Administrative Revenue Growth | +10.34% | -6.05% | +12.26% | +0.55% | +5.70% | +9.37% | +5.42% | -12.02% | +6.87% | -6.22% | +8.60% | +1.02% | +13.52% | +57.99% | +11.58% | -4.52% | +6.49% | -10.33% | +11.22% | -1.44% | +21.34% | +9.45% | -19.84% | -7.74% | +13.87% | +1.00% | +0.09% | -6.14% | n/a |
| Research and Development Revenue | 5.01M | 3.89M | 3.92M | 4.05M | 2.64M | 2.32M | 2.4M | 2.42M | 2.98M | 2.88M | 2.86M | 2.49M | 2.39M | 1.75M | 3.61M | 3.65M | 3.32M | 3.61M | 3.29M | 3.16M | 3.09M | 5.57M | 5.96M | 3.95M | 5.65M | 5.64M | 5.14M | 4.57M | 4.38M |
| Research and Development Revenue Growth | +28.67% | -0.79% | -3.06% | +53.30% | +13.89% | -3.62% | -0.50% | -18.92% | +3.51% | +0.59% | +14.80% | +4.48% | +36.63% | -51.62% | -1.07% | +9.94% | -8.08% | +9.80% | +4.12% | +2.37% | -44.61% | -6.48% | +50.93% | -30.10% | +0.10% | +9.72% | +12.56% | +4.36% | n/a |